ProFibrix B.V., a Leiden, The Netherlands-based developer of innovative products that help stop bleeding (hemostasis) after surgery, closed a series B follow-on financing of undisclosed amount.
The round was co-led by new investors Vesalius Biocapital and INKEF Capital, with participation from existing investors Index Ventures and Gilde Healthcare Partners.
In conjunction with the funding, Alain Parthoens from Vesalius Biocapital, Dirk Kersten from Gilde Healthcare Partners, and Francesco De Rubertis from Index Ventures will join the board of ProFibrix.
In addition, Jan Ohrstrom, has been named Chief Executive Officer.
The company intends to use the proceeds to progress its lead product Fibrocaps into late stage clinical development, as well as to support the company’s other pipeline programs.
Founded in 2004, ProFibrix has a subsidiary in Seattle, WA, USA.